Building a Broad Pipeline in Cancer

Adicet is actively discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients.

Program
Target
Indication

ADI-001

CD20

NH Lymphoma

     

ADI-002

GPC3

HCC

     

ADI-00x

Undisclosed

Solid Tumors

     

ADI-00x

Multiple

Solid & Heme